El interés en corto de Listed Funds Trust Teucrium 2x Long Daily XRP ETF da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de Listed Funds Trust Teucrium 2x Long Daily XRP ETF. Los datos de interés en corto se actualizan cada dos semanas.

Listed Funds Trust Teucrium 2x Long Daily XRP ETF (ARCA:XXRP), Informe de interés en corto

The Fund invests in financial instruments that the Adviser believes in combination should produce daily returns (before fees and expenses) that correspond to two times (2x) the daily price performance of XRP. However, there can be no guarantee that such a strategy will produce the desired results or that any XRP-related investment will provide returns that closely correlate to those produced by XRP. Generally, XRP-related investments are subject to certain implementation costs and expenses not applicable to direct investments in XRP that will cause the returns of XRP-related investments to differ from those of direct investments in XRP. Additionally, the ability to trade XRP 24 hours a day may give rise to differences in returns of XRP-related investments that trade during standard market hours.

Teucrium 2x Long Daily XRP ETF

securities and exchange commission shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

New ETFs

ETFs

Listed Funds Trust Teucrium 2x Long Daily XRP ETF

XXRP

La SEC da luz verde al ETF de futuros de XRP de ProShares. XRP sube más de un 6 % y refuerza su posición en el mercado cripto.

La SEC aprueba ETF de futuros de XRP de ProShares: el mercado reacciona con un fuerte repunte

Baker Hughes (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BKR#NASDAQ">BKR</a>) has outperformed the market over the past 5 years by 3.04% on an annualized basis producing an average annual return of 16.1%. Currently, Baker Hughes has a market capitalization of $37.27 billion. 
Buying $100 In BKR: If an investor had bought $100 of BKR stock 5 years ago, it would be worth $218.28 today based on a price of $37.62 for BKR at the time of writing.
<h3>Baker Hughes's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1748880913_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

News

Trading Ideas

$100 Invested In Baker Hughes 5 Years Ago Would Be Worth This Much Today

WIIM

LION

Lionsgate Studios shares are trading higher after Liberty 77 Capital reported a 12.6% stake in the company.

The Board of Triller Group Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILLR#NASDAQ">ILLR</a>) ("Triller Group", "the Group" or "the Company") is pleased to announce the completion of its strategic review, resulting in the reorganization of the Group into three interconnected core business units:&nbsp;
<ul>
<li>Social Media (Triller App)</li>
<li>Fintech/Financial Service (AGBA Group)</li>
<li>Combat Sports (BKFC)</li>
</ul>
The Board of the Company extends its gratitude to Mr. Bobby Sarnevesht for his contributions since the acquisition of the predecessor of the Company, or Triller Inc., from its founders in 2019 and wishes him success in his future endeavors.
As the Company enters into an exciting new phase of growth, it is implementing an accelerated 6-month timeline for development, financing, and rapid scaling of the Group's three core units.

ILLR

Triller Group Completes Strategic Review, Reorganizes InTo Three Core Business Units- Triller App, AGBA Group And BKFC

U.S. stocks were mixed, with the Dow Jones index falling around 200 points on Monday.
Shares of Vera Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERA#NASDAQ">VERA</a>) rose sharply during Monday's session after the company <a href="https://www.benzinga.com/news/health-care/25/06/45720783/kidney-health-focused-vera-therapeutics-stock-price-spikes-on-heels-of-successful-trial-data">released ORIGIN Phase 3 trial data.</a>
Participants treated with atacicept for immunoglobulin A nephropathy (IgAN) achieved a 46% reduction from baseline in proteinuria as measured by 24-hour urine protein-to-creatinine ratio (UPCR), with a statistically significant and clinically meaningful 42% reduction in UPCR compared to placebo (p&lt;0.0001) at week 36.
Vera Therapeutics shares jumped 56.6% to $29.67 on Monday.
Here are some other big stocks recording gains in today&#8217;s session.
<ul class="wp-block-list">
<li>Applied Digital Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLD#NASDAQ">APLD</a>) surged 44.8% to $9.89 after the company announced a 250MW AI data center lease with CoreWeave.</li>
<li>Kymera Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KYMR#NASDAQ">KYMR</a>) climbed 33.3% to $39.53 after the company announced clinical data for its Phase 1 Healthy volunteer study of KT-621.</li>
<li>Blueprint Medicines Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPMC#NASDAQ">BPMC</a>) gained 26.2% to $127.93 after the company announced that Sanofi will acquire them for $9.5 billion.</li>
<li>Cleveland-Cliffs Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLF#NYSE">CLF</a>) gained 23.2% to $7.18 after Trump said he would double their tariffs to 50%.</li>
<li>Century Aluminum Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CENX#NASDAQ">CENX</a>) rose 22% to $18.89 after Trump said he would double their tariffs to 50%.</li>
<li>Liquidia Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LQDA#NASDAQ">LQDA</a>) gained 18.2% to $17.64 after the company announced it began shipping its newly FDA-approved Yutrepia. Additionally, Needham raised its price target on the stock from $25 to $32.</li>
<li>REGENXBIO Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGNX#NASDAQ">RGNX</a>) jumped 16.4% to $10.30.</li>
<li>Tempus AI, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEM#NASDAQ">TEM</a>) gained 14.1% to $62.95 after the company introduced its fuses program for precision-based medicine and xM for advanced cancer treatment response monitoring.</li>
<li>First Majestic Silver Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AG#NYSE">AG</a>) rose 10.6% to $6.83.</li>
<li>Steel Dynamics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STLD#NASDAQ">STLD</a>) surged 10.5% to $135.93. Shares of steel and aluminum stocks traded higher after Trump said he would double their tariffs to 50%.</li>
<li>Hecla Mining Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HL#NYSE">HL</a>) gained 10.4% to $5.67.</li>
<li>Nucor Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NUE#NYSE">NUE</a>) gained 10% to $120.20. BMO Capital analyst Katja Jancic upgraded Nucor from Market Perform to Outperform and raised the price target from $140 to $145.</li>
<li>ImmunityBio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBRX#NASDAQ">IBRX</a>) rose 6.2% to $2.8250. ImmunityBio received FDA expanded access authorization for the treatment of Lymphopenia with ANKTIVA in patients with solid tumors</li>
<li>Eldorado Gold Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EGO#NYSE">EGO</a>) rose 6.1% to $21.32.</li>
</ul>
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/cannabis/25/06/45719355/top-3-utilities-stocks-that-may-crash-in-june">Top 3 Utilities Stocks That May Crash In June</a> </li>
</ul>
Photo via Shutterstock

APLD

BPMC

CENX

IBRX

KYMR

LQDA

RGNX

STLD

VERA

Vera Therapeutics, Applied Digital, Kymera Therapeutics And Other Big Stocks Moving Higher On Monday

New AI initiative will co-create gen AI solutions with IBM clients, nurture NYC talent, advance enterprise AI implementations
NEW YORK, June 2, 2025 /PRNewswire/ --&nbsp;IBM (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBM#NYSE">IBM</a>) today announced <a href="https://www.ibm.com/products/watsonx-ai-labs">watsonx AI Labs</a>, a new, developer-first innovation hub in New York City, designed to supercharge AI builders and accelerate AI adoption at scale. watsonx AI Labs connects IBM's enterprise resources and expertise with the next generation of AI developers in order to build breakthrough AI applications for business.&nbsp;

IBM Launches watsonx AI Labs In New York City To Accelerate Enterprise AI Adoption

APLS

Apellis Pharmaceuticals shares are trading higher after Wells Fargo raised its price target on the stock from $26 to $29.

HC Wainwright &amp; Co. analyst Joseph Pantginis downgrades Adlai Nortye (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANL#NASDAQ">ANL</a>) from Buy to Neutral.

Downgrades

Analyst Ratings

HC Wainwright & Co. Downgrades Adlai Nortye to Neutral

Biotech

General

RADX

UPDATE: Radiopharm Theranostics Advances Toward IND Filing And 4Q25 Phase 1 Launch For RV01 Radiopharmaceutical Therapy After Preclinical Data Confirms RV01 Maintained High Tumour Uptake

RBC Capital analyst Michael Siperco assumes OceanaGold (TSX:<a class="ticker" href="https://www.benzinga.com/stock/OGC#TSX">OGC</a>) with a Outperform rating and announces Price Target of C$8.

Price Target

Initiation

TSX:OGC

RBC Capital Assumes OceanaGold at Outperform, Announces Price Target of C$8

Landmark industry collaboration maps threat actor aliases across vendors to accelerate response and strengthen global cyberdefense
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.crowdstrike.com%2Fen-us%2F&amp;esheet=54263673&amp;newsitemid=20250602497894&amp;lan=en-US&amp;anchor=CrowdStrike&amp;index=1&amp;md5=323144393bfa3c05c58631682889cd19">CrowdStrike</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>) and Microsoft today announced a collaboration to bring clarity and coordination to how cyber threat actors are identified and tracked across security vendors. By mapping threat actor aliases and aligning adversary attribution across platforms, the collaboration minimizes confusion caused by different naming systems and accelerates cyber defenders' response against today's and tomorrow's most sophisticated adversaries.

CRWD

CrowdStrike And Microsoft Collaborate To Standardize Adversary Attribution Across Platforms

RBC Capital analyst Michael Siperco assumes K92 Mining (TSX:<a class="ticker" href="https://www.benzinga.com/stock/KNT#TSX">KNT</a>) with a Outperform rating and announces Price Target of C$18.

TSX:KNT

RBC Capital Assumes K92 Mining at Outperform, Announces Price Target of C$18

Roper Technologies's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ROP#NYSE">ROP</a>) short percent of float has risen 6.54% since its last report. The company recently reported that it has 1.74 million shares sold short, which is 1.63% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.2 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Roper Technologies Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1748880031_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Roper Technologies has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Roper Technologies's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Roper Technologies's peer group average for short interest as a percentage of float is 3.12%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

What's Driving the Market Sentiment Around Roper Technologies?

Radiopharm Theranostics shares are trading higher after the company announced preclinical data from studies with the Lu177-B7H3-monoclonal antibody RV01.

TJX Companies's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TJX#NYSE">TJX</a>) short percent of float has fallen 3.79% since its last report. The company recently reported that it has 14.32 million shares sold short, which is 1.27% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.97 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>TJX Companies Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1748880025_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for TJX Companies has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing TJX Companies's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, TJX Companies's peer group average for short interest as a percentage of float is 14.91%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

How Is The Market Feeling About TJX Companies?

Adobe's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ADBE#NYSE">ADBE</a>) short percent of float has risen 3.62% since its last report. The company recently reported that it has 9.76 million shares sold short, which is 2.29% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.76 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Adobe Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1748880020_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Adobe has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Adobe's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Adobe's peer group average for short interest as a percentage of float is 3.09%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

ADBE

Looking Into Adobe's Recent Short Interest

Looking into the current session, CRH Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRH#NYSE">CRH</a>) shares are trading at $90.66, after a 0.55% drop. Over the past month, the stock fell by 3.85%, but over the past year, it actually increased by 17.44%. With questionable short-term performance like this, and great long-term performance, long-term shareholders might want to start looking into the company's price-to-earnings ratio. 

<img src="https://www.benzinga.com/files/images/story/2025/1748880020_0_0.png" alt="Past Year Chart" />

<h3>How Does CRH P/E Compare to Other Companies?</h3>
The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against it's past earnings, historical data and aggregate market data for the industry or the indices, such as S&amp;P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also could indicate that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future. 
CRH has a lower P/E than the aggregate P/E of 21.65 of the Construction Materials industry. Ideally, one might believe that the stock might perform worse than its peers, but it's also probable that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1748880020_1.png" alt="Guage" />

In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions.

Intraday Update

Markets

Price Over Earnings Overview: CRH

Crocs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CROX#NASDAQ">CROX</a>) has outperformed the market over the past 15 years by 5.04% on an annualized basis producing an average annual return of 17.11%. Currently, Crocs has a market capitalization of $5.71 billion. 
Buying $1000 In CROX: If an investor had bought $1000 of CROX stock 15 years ago, it would be worth $10,715.79 today based on a price of $101.80 for CROX at the time of writing.
<h3>Crocs's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1748880015_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CROX

Here's How Much You Would Have Made Owning Crocs Stock In The Last 15 Years

Shaquille O&#8217;Neal is a Hall of Famer and one of the most dominant NBA players in history, but even he had moments early in his career where he struggled to handle the spotlight. One of those moments resulted in a life lesson from his late stepfather that would stay with him forever.
<h2 class="wp-block-heading">A Lesson In Perspective</h2>
After a rough game against the New York Knicks during his rookie season with the Orlando Magic, O&#8217;Neal felt overwhelmed. &#8220;I let the pressure get to me,&#8221; he recalled in a 2024 <a href="https://www.youtube.com/watch?v=OgPUs9royFc">interview</a>. His stepfather, the late Army drill sergeant Phillip Harrison, wasn't having it.
He called his son and told him to come home immediately. &#8220;Be here tomorrow at 0500 a.m.,&#8221; Harrison instructed. &#8220;Yes, sir,&#8221; Shaq replied.
Don't Miss:
<ul class="wp-block-list">
<li>Hasbro, MGM, and Skechers trust this AI marketing firm — <a href="https://www.benzinga.com/money/rad-intel">Invest before it's too late.</a></li>
<li><a href="https://www.benzinga.com/money/this-ai-imaging-technology-has-been-used-in-more-than-500-surgeries-now-you-can-be-part-of-the-ai-imaging-revolution">Be part of the next med-tech breakthrough for only $350 — 500+ surgeries already done with nView's AI system.</a></li>
</ul>
Shaq showed up on time the next morning, and they drove in silence. When O&#8217;Neal spoke, his stepfather snapped, clearly <a href="https://www.benzinga.com/personal-finance/25/01/42953411/nba-star-shaq-learned-true-meaning-of-pressure-after-his-dad-took-him-to-a-homeless-family-he-paid-36000-to-get-them-off-the-streets">angry that Shaq had let pressure get to him</a>. As they drove under a bridge, they saw a homeless family sleeping in a tent. They waited in the car, silently, for more than an hour as the family slowly woke up — first the man, then his wife, and finally two young children.&nbsp;
&#8220;He said, &#8216;What happened to the game yesterday?&#8217; I said, &#8216;Man, I don&#8217;t know. I let the pressure get to me.'&#8221; Harrison then gave it to him straight: &#8220;That&#8217;s pressure. Pressure is when you don&#8217;t know when your next meal is coming from.&#8221;
O&#8217;Neal retold the same story in a recent <a href="https://www.youtube.com/watch?v=gsraQqbPjl0">interview</a> on &#8220;The Tonight Show Starring Jimmy Fallon,&#8221; where he emphasized his stepfather&#8217;s frustration with athletes who complain. Harrison had said, &#8220;I&#8217;m tired of you spoiled, rich athletes making all this money who don&#8217;t perform at the level that you&#8217;re supposed to perform to, blaming it on pressure.&#8221;
Trending: Invest where it hurts — and help millions heal:<a href="https://www.benzinga.com/money/a-cure-for-osteoarthritis-powered-by-everyday-investors-cytonics-is-looking-to-beat-big-pharma-and-disrupt-a-390-billion-market"> Invest in Cytonics and help disrupt a $390B Big Pharma stronghold</a>.
That moment changed O&#8217;Neal&#8217;s perspective. He got out of the car and spoke to the man, who had recently lost his job and was struggling to take care of his wife and two kids. Moved by the encounter, Shaq called a friend and arranged a three-bedroom apartment for the family for $36,000. He also found the man a job through another contact.
Two years later, the man had started his own lawn service business and was cutting Shaq&#8217;s grass in Orlando, Florida.
&#8220;Pressure to me is when you don&#8217;t know where your next meal is coming from,&#8221; O&#8217;Neal told Jimmy Fallon. &#8220;So I don&#8217;t really believe in the word &#8216;pressure&#8217; anymore.&#8221;
See Also: <a href="https://www.benzinga.com/money/are-you-rich">Are you rich?</a> Here&#8217;s what Americans think you need to be considered wealthy.
<h2 class="wp-block-heading">Putting Family First</h2>
Shaq&#8217;s appreciation for his parents showed up in other major ways. When he signed his first NBA contract in 1992, he didn't just buy them gifts—he <a href="https://www.benzinga.com/24/11/42118033/nba-legend-shaq-put-his-mom-and-dad-on-payroll-when-he-made-it-big-in-basketball-now-you-making-half-a-million-a-year">put them on the payroll</a>.
&#8220;The first thing I did was incorporate &#8216;Shaq,&#8217; and then I put my mom on salary and put my dad on salary,&#8221; he said in a 2022 <a href="https://www.youtube.com/watch?v=RXMpMHPgk7I">interview</a> on &#8220;Drink Champs.&#8221;
His stepfather was earning $60,000 in the Army. Shaq asked him, &#8220;How much you make in the Army?&#8221; When Harrison said the number, Shaq replied, &#8220;Now you making half a million a year.&#8221; Harrison cried.
Shaq asked his mom what she wanted to make and ended up paying her $750,000 annually.
Read Next: The average American couple has saved this much money for retirement —<a href="http://www.benzinga.com/money/smartasset"> How do you compare</a>?
Image: Shutterstock

Shaq's Dad Once Showed Him A Homeless Family And Said: I'm Tired Of You Spoiled, Rich Athletes Who Don't Perform And Blame It On Pressure

Regeneron Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) on Monday released interim results from the ongoing Phase 2 COURAGE trial.
The company is investigating novel combinations of Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) Wegovy (semaglutide) (GLP-1 receptor agonist) and trevogrumab (anti-GDF8/anti-myostatin) with or without garetosmab <a href="https://www.benzinga.com/topic/weight-loss" target="_blank" rel="noreferrer noopener">(anti-activin A) for obesity</a>.
The trial demonstrated:
<ul class="wp-block-list">
<li>Approximately 35% of semaglutide-induced weight loss was due to loss of lean mass</li>
<li>Combining semaglutide with trevogrumab with or without garetosmab helped preserve lean mass while <a href="https://www.benzinga.com/pressreleases/25/06/g45717752/interim-results-from-ongoing-phase-2-courage-trial-confirm-potential-to-improve-the-quality-of-sem" target="_blank" rel="noreferrer noopener">increasing loss of fat mass</a>.</li>
<li>Wegovy patients shed about 23 pounds in the study, about 7.9 pounds of which constituted lean mass.</li>
<li>The trevogrumab and low-dose Wegovy combo led to about 21.6 pounds of weight loss, with 3.7 pounds in lean mass.</li>
<li>At a higher dose, the trevogrumab combo therapy showed a weight loss of 24.8 pounds; 4.2 pounds in lean mass.</li>
<li>A triplet combination of semaglutide plus trevogrumab plus garetosmab showed a weight loss of 30 pounds and 2 pounds in lean mass.</li>
</ul>
Also Read: <a target="_blank" href="https://www.benzinga.com/trading-ideas/movers/25/05/45692578/regeneron-sanofi-stock-falls-after-uneven-smokers-lung-drug-data" rel="noreferrer noopener">Regeneron, Sanofi Stock Falls After Uneven Smoker&#8217;s Lung Drug Data</a>
The<a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41208078/regeneron-chief-flags-health-risks-with-popular-weight-loss-medications-like-ozempic-says-company" rel="noreferrer noopener"> combination of semaglutide</a> with trevogrumab was generally well-tolerated; the triplet combination of semaglutide with both antibodies had a substantially higher rate of discontinuations due to tolerability issues and other adverse events, consistent with the safety profile previously seen with garetosmab alone.
After 26 weeks, patients enter into the weight-maintenance phase, receiving either higher-dose trevogrumab monotherapy or a placebo through the end of the trial (week 52).
Data from this phase are not yet available.
Regeneron also announced a strategic in-licensing agreement with Hansoh Pharmaceuticals Group Company Limited. The company acquired clinical development and commercial rights outside the Chinese Mainland, Hong Kong and Macau for a dual GLP-1/GIP receptor agonist <a href="https://www.benzinga.com/pressreleases/25/06/g45717858/regeneron-expands-clinical-stage-obesity-portfolio-with-strategic-in-licensing-of-novel-dual-glp-1" target="_blank" rel="noreferrer noopener">currently in Phase 3 testing</a>.
Therapeutic candidate (HS-20094) – studied in over 1,000 patients and administered weekly subcutaneous injections – has demonstrated promising efficacy and safety clinical data, suggesting a potentially similar profile to the only FDA-approved GLP-1/GIP receptor agonist.
A Phase 3 trial in obesity in China and a Phase 2b study in diabetes are ongoing.
Regeneron will pay Hansoh $80 million upfront. The deal may include additional payments of up to $1.93 billion if certain milestones are achieved.
Potential royalties for global net sales outside designated territories would be in the low double digits.
The company says the complementary asset enables synergy and flexibility across Regeneron&#8217;s broad pipeline of obesity and metabolic programs focused on improved quality of weight loss, co-morbidities, and long-term health.
Price Action: REGN stock is down 0.24% at $489.10 at the last check on Monday
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/hedge-funds/25/06/45725058/loeb-rides-nvidias-ai-wave-bets-big-on-atts-telecom-comeback" target="_blank" rel="noreferrer noopener">Loeb Rides Nvidia&#8217;s AI Wave, Bets Big On AT&amp;T&#8217;s Telecom Comeback</a></li>
</ul>
Image: Shutterstock

Large Cap

Health Care

REGN

Regeneron's Obesity Trial With Novo Nordisk's Wegovy Hits Lean Target

RBC Capital analyst Michael Siperco assumes Artemis Gold (XATS: ARTG) with a Outperform rating and announces Price Target of C$32.

Comments

Listed Funds Trust Teucrium 2x Long Daily XRP ETF

Interés en corto

Listed Funds Trust Teucrium 2x Long Daily XRP ETF (ARCA:XXRP), Informe de interés en corto

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL